Michèle Rivasi dénonce le retard inacceptable de la commission européenne, chargée d’établir des critères de définition des perturbateurs endocriniens
La Commission européenne, chargée d’établir des critères de définition des perturbateurs endocriniens, devait se positionner au plus tard, le 13 décembre 2013…
Michèle Rivasi, députée européenne EELV, fondatrice du @CRIIREM et la @CRIIRAD a appris que cette échéance ne sera pas tenue, et que la stratégie européenne risquait de ne jamais voir le jour. Michèle Rivasi dénonce ce retard inacceptable, alerte l’opinion publique sur le lobby de l’industrie pétro-chimique et encourage des actions de la société civile et des politiques contre le sabotage et l’instrumentalisation de la science qui se tient actuellement.
Cross-cultural tale of two women brought together by the intersections of television and industrial agriculture, fertility and motherhood, life and love by Ruth Ozeki
When documentary maker Jane Takagi-Little finally lands a job producing a Japanese television show that just happens to be sponsored by an American meat-exporting business, she uncovers some unsavoury truths about love, fertility, and a dangerous hormone called Diethylstilbestrol (DES). Soon she will also cross paths with Akiko Ueno, a beleaguered Japanese housewife struggling to escape her overbearing husband. And the battle with ‘big beef’ will be on in earnest.
DES is incorporated into the plot, but appears more centrally at the novel’s end than at its beginning. My Year of Meats follows a bi-racial filmmaker named Jane as she makes a series of episodes for Japanese television about how American women prepare beef – Jane’s work is paid for and sponsored by BEEF-EX, a US-based meat lobby seeking to expand its market in Japan. Jane films a series of US families, each of them making a beef-based dinner. Along the way, Jane – who is a DES daughter – investigates the beef industry in the US, the use of DES in cattle feed, and the effects of DES on people exposed to DES in the food industry and agribusiness as well as in medicine.
Ruth Ozeki‘s much-loved debut novel, winner of the Kirayama Prize for Literature of the Pacific Rim, represents the entertaining face of ecological activism. My Year of Meats will delight fans of Michael Pollan, Margaret Atwood and Barbara Kingsolver. Find it on Amazon – on GoodReads.
Children with autism often take multiple drugs, despite limited evidence about the drugs’ long-term safety
Children with autism often take multiple drugs, despite limited evidence about the drugs’ long-term safety.
The objectives of this study were to examine rates and predictors of psychotropic use and multiclass polypharmacy among commercially insured children with autism spectrum disorders (ASD).
This retrospective observational study used administrative medical and pharmacy claims data linked with health plan enrollment and sociodemographic information from 2001 to 2009. Children with ASD were identified by using a validated ASD case algorithm. Psychotropic polypharmacy was defined as concurrent medication fills across ≥2 classes for at least 30 days. Multinomial logistic regression was used to model 5 categories of psychotropic use and multiclass polypharmacy.
Among 33 565 children with ASD, 64% had a filled prescription for at least 1 psychotropic medication, 35% had evidence of psychotropic polypharmacy (≥2 classes), and 15% used medications from ≥3 classes concurrently. Among children with polypharmacy, the median length of polypharmacy was 346 days. Older children, those who had a psychiatrist visit, and those with evidence of co-occurring conditions (seizures, attention-deficit disorders, anxiety, bipolar disorder, or depression) had higher odds of psychotropic use and/or polypharmacy.
Despite minimal evidence of the effectiveness or appropriateness of multidrug treatment of ASD, psychotropic medications are commonly used, singly and in combination, for ASD and its co-occurring conditions. Our results indicate the need to develop standards of care around the prescription of psychotropic medications to children with ASD.
The Yellow Card Scheme is the main adverse drug reactions reporting scheme in the UK
The MHRA and the Commission on Human Medicines (CHM) run the UK’s spontaneous adverse drug reaction (ADR) reporting scheme – called the Yellow Card Scheme. This receives reports of suspected adverse drug reactions (ADRs) or side effects from healthcare professionals and patients for medicines and vaccines.
The Yellow Card Scheme is the main ADR reporting scheme in the UK and was introduced in 1964 after the thalidomide tragedy highlighted the urgent need for routine monitoring of medicines. It receives about 25,000 reports of possible side effects each year.
Keeping up with all the information being thrown at you can be overwhelming
Catherine Pearson assembled a list of eight of the biggest health research findings about preconception, pregnancy and childbirth to come out in the last 12 months — with the caveat that science is a process and any finding requires replication and verification before it’s considered definitive.
Sleep and diet can affect fertility
Specific fertility treatments lead to more multiple births
Miscarriage is more common than most people know
Maternal exercise benefits newborns’ brains
Junk food addiction may start in the womb
Pregnancy interventions are common … and not always welcome
Information and key concerns for policy-makers on endocrine disruptors
An assessment of the state of the science of endocrine disruptors prepared by a group of experts for the United Nations Environment Programme (UNEP) and WHO
Watch the Diaporama, and the DES research photo set on flickr®
If you already have a flickr® account, add us as a contact
Email your photos to firstname.lastname@example.org with a short description and title
The nipple aspirate test and breast cancer screening
Some companies are marketing a new test—the nipple aspirate test—as the latest and greatest tool in early breast cancer screening. But FDA warns that the nipple aspirate test is no substitute for a mammogram.
FDA Abstract :
A nipple aspirate device is a type of pump used to collect fluid from a woman’s breast. A nipple aspirate test can determine whether the fluid collected from the breast contains any abnormal cells.
The FDA is alerting the public, including women and health care providers, that a nipple aspirate test is not a replacement for mammography, other breast imaging tests, or breast biopsy, and should not be used by itself to screen for or diagnose breast cancer. The FDA is not aware of any valid scientific data to show that a nipple aspirate test by itself is an effective screening tool for any medical condition including the early detection of breast cancer or other breast disease.
The FDA, other public health agencies, and national medical and professional societies agree that mammography is the most effective method for detecting breast cancer in its earliest, most treatable stages. These organizations include the American Cancer Society, the American College of Radiology, the Centers for Disease Control and Prevention, the National Cancer Institute, and the Society for Breast Imaging. The National Comprehensive Cancer Network (NCCN) 2013 guidelines state that the clinical utility of nipple aspiration is still being evaluated and it should not be used as a breast cancer screening technique.
Summary of Problem and Scope:
Certain manufactures are promoting the use of nipple aspirate tests as a stand-alone evaluation tool for screening and diagnosing breast cancer, claiming they are an alternative to biopsy or mammography. They also claim that a nipple aspirate test can detect pre-cancerous abnormalities and diagnose breast cancer before mammography with just a sample of a few cells. The FDA is concerned that women will believe these misleading claims about a nipple aspirate test and not get mammograms and/or other needed breast imaging tests or biopsies. This may lead to serious adverse health consequences.
Possible health consequences include false negative test results, indicating the absence of breast cancer when cancer exists, and false positive test results, indicating the presence of breast cancer when none exists. False negative results may lead to delayed diagnosis and/or delayed treatment of breast cancer, with increased risk of serious illness or death. False positive results may lead to needless patient anxiety, along with unnecessary additional testing and treatment.
Recommendations for Patients:
Remember that a nipple aspirate test, such as Atossa Genetics Inc.’s Mammary Aspiration Specimen Cytology Test (MASCT) and/or ForeCYTE Breast Health Test systems, or the HALO Breast Pap Test, is not a substitute for mammography, other breast imaging tests, or breast biopsy, and should not be used by itself for breast cancer screening or diagnosis.
If you have had a nipple aspirate test as a stand-alone evaluation tool for screening and diagnosing breast cancer, you should request a mammogram from your health care provider to get accurate results.
Undergo regular mammograms according to screening guidelines or as recommended by your health care provider.
Recommendations for Health Care Providers:
Do not use a nipple aspirate test as a substitute for mammography or by itself for breast cancer screening or diagnosis.
The FDA has taken action against certain manufacturers promoting nipple aspirate tests as a stand-alone tool for screening and diagnosing breast cancer.
In February 2013, the FDA sent a warning letter to Atossa Genetics, Inc. for the marketing and promotion of a nipple aspirate test for uses that had not received FDA marketing clearance or approval. In this warning letter, the FDA instructed the manufacturer to immediately stop making inappropriate claims about nipple aspirate tests.
In October 2013, Atossa Genetics Inc. initiated a voluntary recall to remove the ForeCYTE Breast Health Test and the Mammary Aspiration Specimen Cytology Test (MASCT) from the market. The FDA classified this recall as Class I, which means that the product is dangerous or defective and has a reasonable chance of causing serious health problems or death.
The FDA will continue to monitor the promotional activity of nipple aspirate test manufacturers, and keep the public and practitioners informed as new information becomes available.
Exposure to valproate, thalidomide or alcohol during the first trimester of pregnancy may change the ultrastructure of the placenta
Valproate, thalidomide and alcohol (ethanol) exposure during the first trimester of pregnancy is known to cause several developmental disorders. All these teratogens are known to pass the placental barrier and interfere directly with the normal development of the fetus. However, these teratogens also alter the formation and function of the placenta itself which may in turn affect the proper nourishment and development of the fetus. Optimum development of the placenta requires adequate invasion of trophoblast into the maternal uterine tissues. Changes in the migratory behavior of trophoblast by maternal exposure to these teratogens during placentogenesis may therefore alter the structure and function of the placenta.
In the present study, the effects of sodium valproate, thalidomide and alcohol on the migration of human first trimester trophoblast cell line (HTR-8/SVneo) were examined in vitro. Cells were cultured in the wells of 48-well culture plates as mono or multilayers. Circular patches of cells were removed from the center of the wells by suction, and the migration of cells into the wound was studied using microscopy. Effects of low and high concentrations of valproate, thalidomide and alcohol were examined on the healing of wounds and on the migration rate of cells by determining the wound areas at 0, 3, 6, 12, 24 and 48 h. Effects of drugs and alcohol on the proliferation and the expression levels of integrin subunits beta1 and alpha5 in cells were examined.
The migration rates of trophoblast differed between wounds created in mono and multilayers of cells. Exposure to teratogens altered the migration of trophoblast into mono and multilayer wounds. The effects of valproate, thalidomide and alcohol on the proliferation of cells during the rapid migratory phase were mild. Drug exposure caused significant changes in the expression levels of beta1 and alpha5 integrin subunits.
Results suggest that exposure to valproate, thalidomide or alcohol during the first trimester of pregnancy may change the ultrastructure of the placenta by altering the migration of trophoblast cells and this effect may be mediated by drug- or alcohol-induced changes in the expression levels of beta1 and alpha5 integrin subunits.